» Articles » PMID: 12642870

Mutations of TP53 Induce Loss of DNA Methylation and Amplification of the TROP1 Gene

Overview
Journal Oncogene
Date 2003 Mar 19
PMID 12642870
Citations 18
Authors
Affiliations
Soon will be listed here.
Abstract

p53 and DNA methylation play key roles in the maintenance of genome stability. In this work, we demonstrate that the two mechanisms are linked and that p53 plays a role in the maintenance of the DNA methylation levels. The loss of p53 was shown to induce loss of DNA methylation in the TROP1 gene, a human cancer-expressed locus that undergoes amplification when hypomethylated. This demethylation was reverted by the reintroduction of a wild-type TP53 (wtTP53) in the TP53-null cells. Using a gene-amplification assay in vivo, we demonstrate that the loss of p53 leads to a demethylation-dependent TROP1 gene amplification. The induction of gene amplification was reverted by the expression of a wtTP53 gene or by in vitro methylation of the transfected DNA with the Sss I DNA methylase. Taken together, these findings demonstrate that the inactivation of TP53 induces loss of DNA methylation and DNA methylation-dependent gene amplification.

Citing Articles

Roles of the NR2F Family in the Development, Disease, and Cancer of the Lung.

Yang J, Sun W, Cui G J Dev Biol. 2024; 12(3).

PMID: 39311119 PMC: 11417824. DOI: 10.3390/jdb12030024.


Can social adversity alter the epigenome, trigger oral disease, and affect future generations?.

Khalid S, Kearney M, McReynolds D Ir J Med Sci. 2024; 193(5):2597-2606.

PMID: 38740675 PMC: 11450135. DOI: 10.1007/s11845-024-03697-3.


A non-mutated fingerprint in cancer genetics.

Guerra E, Di Pietro R, Stati G, Alberti S Front Oncol. 2023; 13:1151090.

PMID: 37456256 PMC: 10338868. DOI: 10.3389/fonc.2023.1151090.


Understanding the versatile roles and applications of EpCAM in cancers: from bench to bedside.

Liu Y, Wang Y, Sun S, Chen Z, Xiang S, Ding Z Exp Hematol Oncol. 2022; 11(1):97.

PMID: 36369033 PMC: 9650829. DOI: 10.1186/s40164-022-00352-4.


Pharmacogenetic and pharmacogenomic discovery strategies.

Crisafulli C, Romeo P, Calabro M, Epasto L, Alberti S Cancer Drug Resist. 2022; 2(2):225-241.

PMID: 35582724 PMC: 8992635. DOI: 10.20517/cdr.2018.008.